A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

Mahmoud A Khaimi Dean McGee Eye Institute, Oklahoma City, OK, USA Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty.Methods: Th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Khaimi MA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/788604a75ed14273a9b9762b4b64c71f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!